We assessed the effect of sleep benefit on motor performance in @entity191 ( @entity191 ) and analyzed its relation to pharmacologic and sleep measures. The sleep benefit phenomenon-motor improvement after sleep before drug intake-in @entity1 with @entity191 has been addressed by questionnaire studies, but objective data are scarce. Ten @entity191 @entity1 with sleep benefit were pairwisely matched to 10 @entity191 @entity1 without sleep benefit for gender, age, @entity191 symptom duration, and medications. We examined motor performance at night before sleep, during morning baseline state immediately after spontaneous awakening, and continuously after intake of the usual levodopa dose. Plasma levodopa concentrations were measured serially and all-night polysomnography was performed. Between night and morning evaluations, motor state improved slightly in @entity1 with sleep benefit and deteriorated slightly in @entity1 without sleep benefit. The difference between both groups proved to be significant. After levodopa induced "on" state, @entity1 with sleep benefit had more severe interdose "off" than those without. Levodopa concentrations and polysomnographic findings were similar in both conditions, although there was a trend toward more abnormal sleep measures in sleep benefit @entity1 . Sleep benefit is a small but significant phenomenon. It does not clearly relate to a specific sleep variable; however, @entity1 with sleep benefit showed a different response profile to levodopa. Subjective perception or possibly sensory mechanisms could play an additional role in sleep benefit in @entity191 .

A clinical, pharmacologic, and polysomnographic study of sleep benefit in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity191 :: ('MESH:D010300', 'Disease') :: ['PD', "Parkinson's disease"]
@entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']
